PTO

PTO/SB/05 (2/98)

Approved for use through 09/30/2000, OMB 0651-0032

, Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

UTILITY PATENT APPLICATION **TRANSMITTAL**

Attomey Docket No.		PC10795A					
First Named Inventor or Application Identifier			Luzzio, et al.				
Title	THIOPHENE D	DERIVATIVES USEFUL AS ANTICANCER AGENTS					
Express Mail Label No.		FI 639817	785US				

	_	A DD1	ICATION EL ELLE					A1-1-	nt Commission		
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application contents.				ADDRESS TO: Assistant Commissioner for Patent Box Patent Application					1 <u>1</u>		
1.		*Fee Transmittal Form (e.g., PTO/SB/17)			<u> </u>	Washington, DC 20231					55.
			, and a duplicate for fee p			Microfiche Computer Program (Appendix)					200
2.		Specification (preferred arra	Total Pa Engement set forth be		 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) 					mission	09/8
			e title of the Inventior erences to Related A			а	Com	puter Readal	ble Copy		J.
			Regarding Fed spon			b.	Pape	er Copy (iden	tical to compu	iter copy)	
124		- Reference	in Microfiche Appen	dix		c.	¬		ng identity of a		20
1.[ACCOMPANYING APPLICATION PARTS						
(II		- Brief Summary of the Invention		8.							
15.	 Brief Description of the Drawings (if filed) Detailed Description Claim(s) 			1	H Ass	ignment	Papers (cove	r sheet & doo			
I. I.				9.	9 37 C.F.R. §3.73(b) Statement Power of Attorney (when there is an assignee)						
1.7		- Abstract of	f the Disclosure					•	•		
1.7					10.	Eng	ilish Tran	slation Docur	ment (<i>if applic</i>	able)	
	3.	Drawing(s) (35	5 U.S.C. 11.3)[Total s	heets []	11.			Disclosure DS)/PTO-144		Copies of IC	os
	4. 🔀	Oath or Declar	ration [Total p	pages [4 -]	12.	Prel	iminary A	Amendment			į
1.) I		a Newly executed (original or copy)				13. Return Receipt Postcard (MPEP 503)					
,			from a prior application	on (37 CFR		(Sh	ould be s	pecifically ite	mized)		
-27	§1.63(d)) 14. *Small Entity Statement filed in prior application										
a might		(101 201	ntinuation/divisional with Note Box 5		İ		ement(s) O/SB/09-		tus still proper	r and desire	ed
		i. [DELETION OF I	•	15			•			
		Signe	d statement attached	deleting	15.			y of Priority [ority is claime			
ł		invent	tor(s) named in the pi	ior application.		(11 10	neigh phi	only is claime	,u)		
_			7 C.F.R. §§1.63(d)(2)								
5.			By Reference (useable of the prior configuration		16.	Othe		riority claim t	o U.S. Provisi	onal pater	it
]	copy of	the oath or de	of the prior application	on, from which a under Box 4b is			a _l	pplication no. ereby incorpo	60/209,686 fi rated by refer	iled June 6	, 2000,
1	copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying			ĺ			ntirety.	nated by relei	ence in its		
ļ	applicat	tion and is her	eby incorporated by i	reference therein.							
1					NOTE	FOR ITEMS 1	& 14: IN OF	RDER TO BE EN	TITLED TO PAY S	MALL ENTIT	,
1					FEES.	A SMALL ENT	ITY STATE	MENT IS REQUIR	RED (37 C.F.R. § 1 IED UPON (37 C.F	27) FYCEDT	·
17	. If a C	ONTINUING A	APPLICATION, check	appropriate box, and su							
		Continuation	Divisional	Continuation				ior application		omen.	
	Prior application information: Examiner Group/Art Unit:										
	18. CORRESPONDENCE ADDRESS										
	Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) or Correspondence address below										
Na	Name Paul H. Ginsburg										
Ad	Address Pfizer Inc										
	Address 235 East 42nd Street, 20th Floor										
Cit	City New York State		Ne	New York			5	-			
	untry	United States	s Of America	Telephone		12)573-2369		Fax			
	ALAME (D.: (A.). A.I. D.										
	Signature A D LOOM						Date	, igonity	41,406 Tue 4	2001	\dashv
			,,,,	1					100 7/	<i>a</i> w)	

UTILITY TRANSMITTAL PTO SB 05, 3/99, (1/1)

PTO/SB/17(2/98)

Approved for use through 09/30/2000.

OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

FEE TO ANGMITTAL	Complete if Known							
FEE TRANSMITTAL	Application Number				Not Yet Assigned			
Potent 6	Filin	g Date			Herewith			
Patent fees are subject to annual revision on October 1. These are the fees effective October 1, 1997.		Named	Invento		Luzzio, et al.			
Small Entity payments <u>must</u> be supported by a small entity statement otherwise large entity fees must be paid. See Forms PTO/SB/09-12.	Examiner Name				Not Yet Assigned			
See 37 C.F.R. §§ 1.27 and 1.28	Grou	p/Art Un	:+					
Total Amount of Payment (\$) 1574		ney Doc			Not Yet Assigned			
METHOD OF PAYMENT (check one)	===				PC10795A			
1. \(\) The commissioner is hereby authorized to charge	3. ADD	DITIONAL	FFFS	FEE	CALCULATION (continued)			
indicated fees and credit any over payments to:		e Entity		II Entity				
Account Number 16-1445	Fee	Fee	Fee	Fee				
Deposit	Code	(\$)	Code	(\$)	Fee Description	Fee Paid		
Account Name	105	130	205	65	Surcharge – late fee or oath			
.Charge Any Additional	127	50	227	25	Surcharge-late provisional filing fee cover sheet	or		
of the Notice of Allowance.	139	130	139	130	Non-English specification	<u> </u>		
2. Payment Enclosed:	147	2,520	147	2,520	For filing a request for reexamination	,		
1.1	112	920*	112	920*	Requesting publication of SIR prior to	,		
	113	1,840*	113	1,840	Examiner action	<u> </u>		
FEE CALCULATION 1. BASIC FILING FEE	115	110	215	55	Extension for reply within first month			
1.71	116	390	216	195	Extension for reply within second month			
Large Entity Small Entity Fee Fee Fee Fee Description Fee Paid	117	890	217	445	Extension for reply within third month			
Code (\$) Code (\$)	118	1,390	218	695	Extension for reply within fourth mont	, 		
104= 710 201 355 Utility filing fee 710	128	1,890	228	945	Extension for reply within fifth month			
106 320 206 160 Design filing fee	119	310	219	155	Notice of Appeal	[]		
100 710	120	310	220	155	Filing a brief in support of an appeal	<u> </u>		
200 Reissue filing fee	121	270	221	135	Request for oral hearing			
7.5 Provisional filing ree	138	1,510	138	1,510	Petition to institute a public use proceeding			
SUBTOTAL (1) (\$) 710	140	110	240	55	Petition to revive - unavoidable			
Extra Fee from	141	1,240	241	620	Petition to revive - unintentional			
Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)			
140 A 18 = 864	143	440	243	220	Design issue fee			
laims 2 - 3**= 0 X 80 = 0	144	600	244	300	Plant issue fee			
or number previously paid, if greater; For Reissues, see below	122	130	122	130	Petitions to the Commissioner			
arge Entity Small Entity	123	50	123	50	Petitions related to provisional applications			
ode (\$) Code (\$)	126	240	126	240	Submission of Information Disclosure			
103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each natent assignment on			
102 80 40 Independent claims in excess of 3	146	710	246	355	Filing a submission after final rejection	<u> </u>		
04 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	(37 CFR 1.129(a)) For each additional invention to be			
09 80 209 40 *Reissue independent claims over original patent	Other Fee (her Fee (specify)			examined (37 CFR 1.129(b))	<u> </u>		
10 18 210 9 **Reissue claims in excess of 20 and over original patent	Other Fee (Other Fee (specify)						
SUBTOTAL (2) (\$) 864	*Reduced b	y Basic Fi	ling Fee l	- Paid	SUBTOTAL (3) (\$)			
nature					Dec. 11			
Han b. Looms	Date	Jue	4,21	201	Deposit Account			
		ال المال	1/20	101	User ID			